About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Recent Updates on the Use of BTK Inhibitors in CLL
By
Andrew Lipsky
162 views
April 10, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
12:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"
Feat.
S. O'Brien,
C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute
Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…
Feat.
A. Winter
50:34
Scripps MD Anderson Cancer Center
The Cure of Leukemias in the Next Decade: An Optimist’s View
Feat.
H. Kantarjian
06:53
UC Irvine Health
Fixed-Duration Treatment in CLL: Current Considerations
Feat.
E. Brem
24:33
Indy Hematology Review
Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…
Feat.
J. Woyach
08:17
Adam Kittai
Highlights From iwCLL 2023: What's New and Practice Informing i…
06:56
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Efficacy of Ibrutinib Arms Across ALPINE an…
Feat.
M. Shadman
10:06
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…
Feat.
J. Woyach
15:21
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat CLL at the MD Anderson Cancer Center
Feat.
A. Ferrajoli
06:34
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…
Feat.
A. Kittai
08:45
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of CLL - Highlights & Key Takea…
Feat.
V. Yazbeck
06:28
Insights from 2023 EHA® Annual Meeting
EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…
Feat.
O. Al-Sawaf
06:21
City of Hope
Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL
Feat.
A. Danilov
18:01
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Pri…
Feat.
J. Rhodes
11:39
5th SOHO Italy Annual Conference
SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the R…
Feat.
G. Gaidano
05:12
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Fixed-Duration Pirtobrutinib Combined With …
Feat.
N. Shah
10:19
Alvaro Alencar
Pirtobrutinib in R/R CLL
13:16
ASH 2022 Conference Coverage
Experts Discuss Key Updates in CLL
Feat.
S. O'Brien,
C. Coombs
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
